Q-omics provides the consensus-scored TCEA1 profile across patient tissues and cancer cell-line models. TCEA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TCEA1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TCEA1 protein abundance shows 22,122 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where TCEA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEA1 survival associations across molecular data types. TCEA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEA1 RNA expression–survival associations across cancer types. High TCEA1 expression shows unfavorable associations in UVM, KIRP, KICH and ACC, but favorable associations in SKCM and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TCEA1 RNA expression.
This table summarizes TCEA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCEA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEA1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRC, LUAD and LUSC. The HNSC box plot shows higher TCEA1 RNA expression in tumor versus normal tissue (log2 FC = +1.228, t-test p < 0.001).
This table shows molecular features associated with TCEA1 in patient tissues and cancer cell lines. In patient samples, TCEA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
